Every material Form 8-K SRX Global Inc. has filed with the SEC since September 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 6, 2026, SRX Global entered a Stock Purchase Agreement to acquire all outstanding stock of CERo Therapeutics, Inc., a wholly owned subsidiary of CERo Therapeutics Holdings, Inc. Consideration includes $1,000,000 in SRX common stock, discharge of a senior secured note with an outstanding principal balance of $8,249,643.77, and assumption of about $1,562,000 in liabilities. Completion depends on a 30-day go-shop period, the acquisition of Holdings' Series C, D and E preferred stock, and conditions tied to its Series A preferred stock, so shareholders face both the share issuance and the uncertainty of closing.
Consideration: $1,000,000 of SRX common stock, discharge of the Consolidated Note (outstanding principal $8,249,643.77 as of the filing date), and assumption of about $1,562,000 in liabilities
30-day go-shop period from the October 6, 2026 signing, conducted by Joseph Gunnar & Co., LLC, during which Holdings may solicit alternative proposals
Holdings must pay a $750,000 termination fee in specified cases; SRX may owe Holdings $750,000 in specified cases involving its failure to fund
Closing requires SRX to acquire Holdings' Series C, D and E preferred stock; the agreement is not subject to a financing condition
SRX Global said it has committed $1.5 million to launch a family of actively managed exchange traded funds through its EMJX platform, in partnership with Kupa AI. The company also intends to distribute its holdings from the ETF launch directly to shareholders, with timing and record date to be announced later. The filing gives no financial results, so the near-term effect on shareholders is not quantified.
SRX committed $1.5 million to launch the ETF family, in partnership with Kupa AI
The first ETF is expected to be available to retail and institutional investors in the first quarter of 2027
The first fund will use a digital asset hedging strategy powered by EMJX's AI-driven regime model
SRX intends to dividend its ETF holdings to shareholders; timing and record date to be announced later
SRX Global entered a Limited Consent and Amendment Agreement on September 8, 2026, under which holders of its Series C convertible preferred stock consented to and waived certain rights so the company can maintain a stock repurchase plan. The plan allows repurchases of up to the lesser of 10,000,000 shares or 50% of outstanding common stock, for an aggregate price not to exceed $20,000,000, through July 7, 2027. The filing does not state how much stock the company has bought back or plans to buy back.
Consent Agreement dated September 8, 2026, between the company and the Required Holders of Series C preferred stock
Repurchase plan cap: lesser of 10,000,000 common shares or 50% of outstanding common stock, up to $20,000,000 in aggregate purchase price
Plan period ends July 7, 2027
Related August 27, 2026 sale of 3,579 Series C preferred shares for $2.825 million; the Series C shares are convertible into common stock
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SRX Global Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →